176 related articles for article (PubMed ID: 34249415)
1. Multi-organ metastasis as destination for breast cancer cells guided by biomechanical architecture.
Lin Q; Chen X; Meng F; Ogawa K; Li M; Song R; Zhang S; Zhang Z; Kong X; Xu Q; He F; Liu D; Bai X; Sun B; Hung MC; Liu L; Wands JR; Dong X
Am J Cancer Res; 2021; 11(6):2537-2567. PubMed ID: 34249415
[TBL] [Abstract][Full Text] [Related]
2. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
3. ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis.
Lin Q; Chen X; Meng F; Ogawa K; Li M; Song R; Zhang S; Zhang Z; Kong X; Xu Q; He F; Bai X; Sun B; Hung MC; Liu L; Wands J; Dong X
Mol Cancer; 2019 Nov; 18(1):156. PubMed ID: 31694640
[TBL] [Abstract][Full Text] [Related]
4. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
Cancer Lett; 2020 Jul; 481():63-75. PubMed ID: 32145343
[TBL] [Abstract][Full Text] [Related]
5. Aspartate β-hydroxylase (ASPH) Accelerates Intrahepatic Cholangiocarcinoma Metastasis
Zou Y; Lin J; Liu J; Zhang F; Yang T; Gong J; Jiang T; Zuo J; Song R; Shen H; Shen F; Li J
Curr Protein Pept Sci; 2023; 24(5):436-446. PubMed ID: 37132101
[TBL] [Abstract][Full Text] [Related]
6. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
7. A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.
Aihara A; Huang CK; Olsen MJ; Lin Q; Chung W; Tang Q; Dong X; Wands JR
Hepatology; 2014 Oct; 60(4):1302-13. PubMed ID: 24954865
[TBL] [Abstract][Full Text] [Related]
8. Hydroxylase Activity of ASPH Promotes Hepatocellular Carcinoma Metastasis Through Epithelial-to-Mesenchymal Transition Pathway.
Zou Q; Hou Y; Wang H; Wang K; Xing X; Xia Y; Wan X; Li J; Jiao B; Liu J; Huang A; Wu D; Xiang H; Pawlik TM; Wang H; Lau WY; Wang Y; Shen F
EBioMedicine; 2018 May; 31():287-298. PubMed ID: 29764768
[TBL] [Abstract][Full Text] [Related]
9. Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.
Nagaoka K; Ogawa K; Ji C; Cao KY; Bai X; Mulla J; Cheng Z; Wands JR; Huang CK
Dig Dis Sci; 2021 Apr; 66(4):1080-1089. PubMed ID: 32445050
[TBL] [Abstract][Full Text] [Related]
10. Aspartate β-hydroxylase as a target for cancer therapy.
Kanwal M; Smahel M; Olsen M; Smahelova J; Tachezy R
J Exp Clin Cancer Res; 2020 Aug; 39(1):163. PubMed ID: 32811566
[TBL] [Abstract][Full Text] [Related]
11. Aspartate-β-Hydroxylase: A Promising Target to Limit the Local Invasiveness of Colorectal Cancer.
Benelli R; Costa D; Mastracci L; Grillo F; Olsen MJ; Barboro P; Poggi A; Ferrari N
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32295249
[TBL] [Abstract][Full Text] [Related]
12. Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma.
Iwagami Y; Huang CK; Olsen MJ; Thomas JM; Jang G; Kim M; Lin Q; Carlson RI; Wagner CE; Dong X; Wands JR
Hepatology; 2016 Apr; 63(4):1213-26. PubMed ID: 26683595
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase.
Kanwal M; Polakova I; Olsen M; Kasi MK; Tachezy R; Smahel M
J Cancer; 2024; 15(11):3466-3480. PubMed ID: 38817852
[No Abstract] [Full Text] [Related]
14. The Tumor Suppressor SASH1 Interacts With the Signal Adaptor CRKL to Inhibit Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
Franke FC; Müller J; Abal M; Medina ED; Nitsche U; Weidmann H; Chardonnet S; Ninio E; Janssen KP
Cell Mol Gastroenterol Hepatol; 2019; 7(1):33-53. PubMed ID: 30480076
[TBL] [Abstract][Full Text] [Related]
15. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL
Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the Relationship Between the Expression of Aspartate β-Hydroxylase and the Pathological Characteristics of Breast Cancer.
Zhang Y; Gao Y; Li Y; Zhang X; Xie H
Med Sci Monit; 2020 Dec; 26():e926752. PubMed ID: 33380715
[TBL] [Abstract][Full Text] [Related]
17. Bio-nanoparticle based therapeutic vaccine induces immunogenic response against triple negative breast cancer.
Bai X; Zhou Y; Lin Q; Huang CK; Zhang S; Carlson RI; Ghanbari H; Sun B; Wands JR; Dong X
Am J Cancer Res; 2021; 11(9):4141-4174. PubMed ID: 34659881
[TBL] [Abstract][Full Text] [Related]
18. Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.
Huang CK; Iwagami Y; Aihara A; Chung W; de la Monte S; Thomas JM; Olsen M; Carlson R; Yu T; Dong X; Wands J
PLoS One; 2016; 11(3):e0150336. PubMed ID: 26954680
[TBL] [Abstract][Full Text] [Related]
19. Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.
Shimoda M; Tomimaru Y; Charpentier KP; Safran H; Carlson RI; Wands J
J Hepatol; 2012 May; 56(5):1129-1135. PubMed ID: 22245894
[TBL] [Abstract][Full Text] [Related]
20. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis.
Yang F; Zhou X; Miao X; Zhang T; Hang X; Tie R; Liu N; Tian F; Wang F; Yuan J
Breast Cancer Res Treat; 2014 May; 145(1):23-32. PubMed ID: 24687377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
